DGX Quest Diagnostics Inc

Price (delayed)

$146.49

Market cap

$17.97B

P/E Ratio

8.63

Dividend/share

$2.42

EPS

$16.97

Enterprise value

$21.63B

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals ...

Highlights
DGX's EPS has surged by 107% year-on-year
DGX's price to earnings (P/E) is 47% lower than its 5-year quarterly average of 16.2 and 7% lower than its last 4 quarters average of 9.3
The net income has soared by 98% YoY but it has contracted by 2.8% from the previous quarter
The gross profit has increased by 47% YoY but it has decreased by 2.2% from the previous quarter

Key stats

What are the main financial stats of DGX
Market
Shares outstanding
122.67M
Market cap
$17.97B
Enterprise value
$21.63B
Valuations
Price to earnings (P/E)
8.63
Price to book (P/B)
2.8
Price to sales (P/S)
1.63
EV/EBIT
7.18
EV/EBITDA
6.34
EV/Sales
1.96
Earnings
Revenue
$11.05B
EBIT
$3.01B
EBITDA
$3.41B
Free cash flow
$1.88B
Per share
EPS
$16.97
Free cash flow per share
$15.24
Book value per share
$52.32
Revenue per share
$89.8
TBVPS
$43.6
Balance sheet
Total assets
$13.57B
Total liabilities
$7.14B
Debt
$4.65B
Equity
$6.39B
Working capital
$1.1B
Liquidity
Debt to equity
0.73
Current ratio
1.62
Quick ratio
1.4
Net debt/EBITDA
1.07
Margins
EBITDA margin
30.9%
Gross margin
40.3%
Net margin
19.8%
Operating margin
23.9%
Efficiency
Return on assets
16.1%
Return on equity
33.9%
Return on invested capital
40.4%
Return on capital employed
25.5%
Return on sales
27.3%
Dividend
Dividend yield
1.65%
DPS
$2.42
Payout ratio
14.3%

DGX stock price

How has the Quest Diagnostics stock price performed over time
Intraday
0.78%
1 week
2.8%
1 month
-4.07%
1 year
15.95%
YTD
22.93%
QTD
0.81%

Financial performance

How have Quest Diagnostics's revenue and profit performed over time
Revenue
$11.05B
Gross profit
$4.45B
Operating income
$2.64B
Net income
$2.18B
Gross margin
40.3%
Net margin
19.8%
The net income has soared by 98% YoY but it has contracted by 2.8% from the previous quarter
DGX's operating income has surged by 72% year-on-year but it is down by 2.4% since the previous quarter
Quest Diagnostics's net margin has surged by 50% YoY but it has decreased by 2.5% QoQ
The gross profit has increased by 47% YoY but it has decreased by 2.2% from the previous quarter

Growth

What is Quest Diagnostics's growth rate over time

Valuation

What is Quest Diagnostics stock price valuation
P/E
8.63
P/B
2.8
P/S
1.63
EV/EBIT
7.18
EV/EBITDA
6.34
EV/Sales
1.96
DGX's EPS has surged by 107% year-on-year
DGX's price to earnings (P/E) is 47% lower than its 5-year quarterly average of 16.2 and 7% lower than its last 4 quarters average of 9.3
Quest Diagnostics's equity has increased by 8% from the previous quarter
The stock's price to book (P/B) is 8% more than its 5-year quarterly average of 2.6 and 3.7% more than its last 4 quarters average of 2.7
The revenue has grown by 32% YoY
The stock's price to sales (P/S) is 9% less than its 5-year quarterly average of 1.8

Efficiency

How efficient is Quest Diagnostics business performance
DGX's return on assets has surged by 89% year-on-year
Quest Diagnostics's return on invested capital has surged by 83% YoY but it has decreased by 3.1% QoQ
DGX's ROE has soared by 80% year-on-year but it is down by 2.6% since the previous quarter
DGX's return on sales is up by 41% year-on-year but it is down by 2.8% since the previous quarter

Dividends

What is DGX's dividend history
DPS
$2.42
Dividend yield
1.65%
Payout ratio
14.3%
Recent dividends

Financial health

How did Quest Diagnostics financials performed over time
The total assets is 90% greater than the total liabilities
Quest Diagnostics's quick ratio has increased by 20% QoQ and by 10% YoY
The current ratio has increased by 17% QoQ and by 16% YoY
Quest Diagnostics's debt is 27% lower than its equity
Quest Diagnostics's debt has decreased by 10% YoY
The company's debt to equity fell by 9% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.